1FW

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	**10/826,972**
Filing Date	**April 16, 2004**
First Named Inventor	**Sung Hwan Moon**
Art Unit	**1624**
Examiner Name	
Attorney Docket No.	**200146.402C4**

ENCLOSURES (*check all that apply*)

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☒ Form PTO-1449 (10 pages)
- ☒ Cited References (X 3)
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts under 37 C.F.R. 1.52 or 1.53
- ☐ Response to Missing Parts/Incomplete Application
- ☐ Drawing(s)
- ☐ Request for Corrected Filing Receipt
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation, Change of Correspondence Address
- ☐ Declaration
- ☐ Statement under 37 CFR 3.73(b)
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD(s), Number of CD(s) _____
- ☐ After Allowance Communication to Technology Center (TC)
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Return Receipt Postcard
- ☐ Additional Enclosure(s) *(please identify below)*:

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Individual Name	**Qing Lin, Ph.D.**	Customer Number 00500
Signature		
Date	**October 21, 2004**	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	**Jennifer J. Fortuny**	
Signature		Date: **October 21, 2004**

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

October 21, 2004
Date

Jennifer J. Fortuny

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Sung Hwan Moon et al.
Application No.	:	10/826,972
Filed	:	April 16, 2004
For	:	REVERSE-TURN MIMETICS AND METHOD RELATING THERETO
Art Unit	:	1624
Docket No.	:	200146.402C4
Date	:	October 21, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the 384 references set forth on the attached Form PTO-1449. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/803,179, filed March 17, 2004; which is a continuation-in-part of U.S Application No. 10/411,877, filed April 9, 2003; which is a continuation-in-part of U.S. Application No. 10/087,443, filed March 1, 2002, now abandoned; which is a continuation-in-part of U.S. Application No. 09/976,470, filed October 12, 2001, now abandoned. The references listed on the attached Forms PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in these prior applications and, therefore, are not required to be provided in this application. However, references CL, DF, and DK of the attached Forms PTO-1449, were

not previously made of record, and accordingly, copies are enclosed herewith. If the Examiner wishes, copies of previously supplied references will be provided upon request. As to any reference supplied herewith or previously supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC



Qing Lin, Ph.D.
Registration No. 53,937

Enclosures:
Form PTO-1449 (10 pages)
Cited References (X 3)

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

(QXL:jjf) 525585_1.DOC

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,440,013	08/08/95	Kahn	530	317	
	AB	5,475,085	12/12/95	Kahn	530	317	
	AC	5,618,914	04/08/97	Kahn	530	317	
	AD	5,670,155	09/23/97	Kahn	424	208.1	
	AE	5,672,681	09/30/97	Kahn	530	317	
	AF	5,693,325	12/02/97	Kahn	424	188.1	
	AG	5,710,245	01/20/98	Kahn	530	324	
	AH	5,840,833	11/24/98	Kahn	530	300	
	AI	5,859,184	01/12/99	Kahn et al.	530	300	
	AJ	5,929,237	07/27/99	Kahn	544	279	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	AK	WO 03/006447 A2	01/23/03	WIPO		
	AL	WO 01/16135 A2	03/08/01	WIPO		
	AM	WO 01/00210 A1	01/04/01	WIPO		
	AN	WO 94/03494 A1	02/17/94	WIPO		

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AO		Arango, D. et al., "c-myc/p53 Interaction Determines Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracie *in Vitro* and *in Vivo*," *Cancer Research 61*: 4910-4915, June 15, 2001.
	AP		Batlle, E. et al., "β-Catenin and TCF Mediate Cell Positioning in the Intestinal Epithelium by Controlling the Expression of EphB/EphrinB," *Cell*, 111:251-263, October 18, 2002.
	AQ		Behrens, J. et al., "Functional interaction of β-catenin with the transcription factor LEF-1," *Nature 382*: 638-642, August 15, 1996.
	AR		Bienz and Clevers, "Linking Colorectal Cancer to Wnt Signaling," *Cell*, 103:311-320, October 13, 2000.
	AS		Blanc-Brude, O. P. et al., "Inhibitor of apoptosis protein surviving regulates vascular injury," *Nature Medicine*, 8(9):987-994, September 2002.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	6,013,458	01/11/00	Kahn et al.	435	7.1	
	BB	6,020,331	02/01/00	Kahn	514	221	
	BC	6,117,896	09/12/00	Qabar et al.	514	384	
	BD	6,184,223 B1	02/06/01	Kahn et al.	514	249	
	BE	6,245,764 B1	06/12/01	Kahn et al.	514	248	
	BF	6,294,525 B1	09/25/01	Stasiak et al.	514	183	
	BG	6,372,744 B1	04/16/02	Qabar et al.	514	248	
	BH	6,413,963 B2	07/02/02	Kahn et al.	514	249	
	BI	6,440,955 B1	08/27/02	Stasiak et al.	514	183	
	BJ	6,548,500 B2	04/15/03	Kahn et al.	514	249	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	BK					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	BL		Caca, K. et al., "β- and γ-Catenin Mutations, but not E-Cadherin Inactivation, Underlie T-Cell Factor/Lymphoid Enhancer Factor Transcriptional Deregulation in Gastric and Pancreatic Cancer," *Cell Growth & Differentiation 10*: 369-376, 1999.
	BM		Cadigan and Nusse, "Wnt signaling: a common theme in animal development," *Genes & Development 11*: 3286-3305, 1997.
	BN		Cheguillaume, A. et al., "New Potential Monomers for Solid Phase Synthesis of Hydrazinopeptoids: the N^{α}-Substituted-N^{β}-Protected Hydrazinoglycines and Hydrazonoglycinals," *Synlett* 2000, No. 3, pgs 331-334, March 2000.
	BO		Chen, S. et al., "Wnt-1 Signaling Inhibits Apoptosis by Activating β-Catenin/T Cell Factor-mediated Transcription," *The Journal of Cell Biology 152*(1): 87-96, January 8, 2001.
	BP		Chenn and Walsh, "Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors," *Science*, 297:365-369, July 19, 2002.
	BQ		Chrivia, J.C. et al., "Phosphorylated CREB binds specifically to the nuclear protein CBP," *Nature 365*: 855-859, October 28, 1993.
	BR		Crawford, H.C. et al., "The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors," *Oncogene*, 18: 2883-2891, 1999.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA	2001/0039274 A1	11/08/01	Kahn et al.	514	221	
	CB	2002/0022620 A1	02/21/02	Kahn et al.	514	221	
	CC	2002/0065416 A1	05/30/02	Stasiak et al.	544	350	
	CD	2002/0068695 A1	06/06/02	Scolastico et al.	514	9	
	CE	2003/0021773 A1	01/30/03	Moroder et al.	424	94.1	
	CF	2003/0027819 A1	02/06/03	Qabar et al.	514	224.2	
	CG	2003/0105103 A1	06/05/03	Golebiowski et al.	514	249	
	CH	2004/0072831 A1	04/15/04	Moon et al.	514	243	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	CI					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	CJ		Daniels, D. L. et al., "β-catenin: molecular plasticity and drug design," *TRENDS in Biochemical Sciences*, 26(11):672-678, November 11, 2001.
	CK		DasGupta and Fuchs, "Multiple roles for activated LEF/TCF transcription complexes during hair follicle development and differentiation," *Development*, 126: 4557-4568, 1999.
	CL		Davis, P.D. et al., "ZD6126: A Novel Vascular-targeting Agent That Causes Selective Destruction of Tumor Vasculature," *Cancer Research*, 62:7247-7253, December 15, 2002.
	CM		De Farrari and Inestrosa, "Wnt signaling function in Alzheimer's disease," *Brain Research Reviews*, 33: 1-12, 2000.
	CN		Dolle, R.E. "Comprehensive Survey of Combinatorial Library Synthesis: 1999," *Journal of Combinatorial Chemistry*, 2(5): 383-433, September/October 2000.
	CO		Dooley and Houghten, "The use of positional scanning synthetic peptide combinatorial libraries for the rapid determination of opioid receptor ligands," *Life Sciences*, 52(18): 1509-1517, 1993.
	CP		Dooley, C.T. et al., "Acetalins: Opioid receptor antagonists determined through the use of synthetic peptide combinatorial libraries," *Proc. Natl. Acad. Sci. USA*, 90: 10811-10815, November 1993.
	CQ		Dooley, C.T. et al., "An All D-Amino Acid Opioid Peptide with Central Analgesic Activity from a Combinatorial Library," *Science 266*: 2019-2022, December 23, 1994.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE - PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	APPLICATION NO.
		200146.402C4	10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS: Sung Hwan Moon et al.	
		FILING DATE: April 16, 2004	GROUP ART UNIT: 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	DA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	DB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	DC		Eckner, R. et al., "Molecular cloning and functional analysis of the adenovirus E1A-associated 300-kD protein (p300) reveals a protein with properties of a transcriptional adaptor," *Genes & Development*, 8: 869-884, 1994.
	DD		Eichler, J. et al., "Cyclic Peptide Template Combinatorial Libraries: Synthesis and Identification of Chymotrypsin Inhibitors," *Peptide Research*, 7(6):300-307, 1994.
	DE		Fraser, P.E. et al., "Presenilin function: connections to Alzheimer's disease and signal transduction," *Biochem. Soc. Symp.*, 67:89-100, 2001.
	DF		Fleisher, D. et al., "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," *Advanced Drug Delivery Reviews*, 19:115-130, 1996.
	DG		Fuchs, E., "Beauty is Skin Deep: The Fascinating Biology of the Epidermis and its Appendages," *The Harvey Lectures, Delivered Under the Auspices of The Harvey Society of New York, 1998-1999*, Wiley-Liss, A John Wiley & Sons, Inc., Publication, Series 94, 47-48, 2000.
	DH		Fujimuro, M. et al., "A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma-associated herpesvirus latency," *Nature Medicine*, 9(3):300-306, March 2003.
	DI		Gallop, M.A. et al., "Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries," *Journal of Medicinal Chemistry*, 37(9):1233-1251, April 29, 1994.
	DJ		Gat, U. et al., "De Novo Hair Follicle Morphogenesis and Hair Tumors in Mice Expressing a Truncated β-Catenin in Skin," *Cell*, 95:605-614, November 25, 1998.
	DK		Golik, J. et al., "Synthesis and Antitumor Evaluation of Paclitaxel Phosphonooxymethyl Ethers: A Novel Class of Water Soluble Paclitaxel Pro-Drugs," *Bioorganic & Medicinal Chemistry Letters*, 6(15):1837-1842, 1996.
	DL		Gomez, M. R., "History of the tuberous sclerosis complex," *Brain & Development*, 17(suppl):55-7, 1995.
	DM		Graminski and Lerner, "A Rapid Bioassay for Platelet-Derived Growth Factor β-Receptor Tyrosine Kinase Function," *Bio/Technology 12*: 1008-1011, October 12, 1994.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	EA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	EB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	EC		Grossman, D. et al., "Inhibition of melanoma tumor growth *in vivo* by surviving targeting," *PNAS*, 98(2):635-640, January 16, 2001.
	ED		Hanai, J., et al., "Endostatin is a potential inhibitor of Wnt signaling," *The Journal of Cell Biology*, 158(3):529-539, August 5, 2002.
	EE		Hartmann, D., "From Alzheimer's disease to skin tumors: The catenin connection," *Proc. Natl. Acad. Sci. USA*, 98(19): 10522-10523, September 11, 2001.
	EF		Hayashi, S. et al., "A *Drosophila* homolog of the tumor suppressor gene adenomatous polyposis coli down-regulates β-catenin but its zygotic expression is not essential for the regulation of Armadillo," *Proc. Natl. Acad. Sci. USA*, 94:242-247, January 1997.
	EG		He, Tong-Chuan et al., "Identification of c-*MYC* as a Target of the APC Pathway," *Science*, 281:1509-1512, September 4, 1998.
	EH		He, Tong-Chuan et al., "PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs," *Cell*, 99:335-345, October 29, 1999.
	EI		Hecht, A. et al., "The p300/CBP acetyltransferases function as transcriptional coactivators of β-catenin in vertebrates," *European Molecular Biology Organization Journal*, 19(9):1839-1850, 2000.
	EJ		Houghten and Dooley, "The use of synthetic peptide combinatorial libraries for the determination of peptide ligands in radio-receptor assays: opioid peptides," *Bioorganic & Medicinal Chemistry Letters*, 3(3):405-412, 1993.
	EK		Houghten, R.A. et al., "Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery," *Nature*, 354:84-86, November 7, 1991.
	EL		Houghten, R.A. et al., "The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides," *BioTechniques*, 13(3):412-421, 1992.
	EM		Hsu, S-C. et al., "Modulation of Transcriptional Regulation by LEF-1 in Response to Wnt-1 Signaling and Association with β-Catenin," *Molecular and Cellular Biology*, 18(8):4807-4818, August 1998.
	EN		Janda, K.D., "Tagged versus untagged libraries: Methods for the generation and screening of combinatorial chemical libraries," *Proc. Natl. Acad. Sci. USA*, 91:10779-10785, November 1994.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	FA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	FB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	FC		Janknecht and Hunter, "A growing coactivator network," *Nature*, 383:22-23, September 5, 1996.
	FD		Kang, D.E. et al., "Presenilin 1 Facilitates the Constitutive Turnover of β-Catenin: Differential Activity of Alzheimer's Disease-Linked PS1 Mutants in the β-Catenin-Signaling Pathway," *The Journal of Neuroscience*, 19(11):4229-4237, June 1, 1999.
	FE		Kim, P.J. et al., "Survivin and molecular pathogenesis of colorectal cancer," *The Lancet*, 362:205-209, July 19, 2003.
	FF		Kinzler and Vogelstein, "Lessons from Hereditary Colorectal Cancer," *Cell*, 87:159-170, October 18, 1996.
	FG		Kolligs, F.T. et al., "Neoplastic Transformation of RK3E by Mutant β-Catenin Requires Deregulation of Tcf/Lef Transcription but Not Activation of c-*myc* Expression," *Molecular and Cellular Biology*, 19(8):5696-5706, August 1999.
	FH		Kosik, K.S., "A partnership that delivers, Alzheimer disease mutations in the presenilins alter the intracellular trafficking of β-catenin, hinting that the presenilins may also determine the fate of other proteins in the endoplasmic reticulum," *Nature Medicine*, 5(2):149-150, February 1999.
	FI		Lam, K.S. et al., "A new type of synthetic peptide library for identifying ligand-binding activity," *Nature*, 354:82-84, November 7, 1991.
	FJ		Levesque, G. et al., "Presenilins Interact with Armadillo Proteins Including Neural-Specific Plakophilin-Related Protein and β-Catenin," *Journal of Neurochemistry*, 72(3):999-1008, 1999.
	FK		Mak, B.C. et al., "The Tuberin-Hamartin Complex Negatively Regulates β-Catenin Signaling Activity," *The Journal of Biological Chemistry*, 278(8):5947-5951, February 21, 2003.
	FL		Mesri, M. et al., "Cancer gene therapy using a survivin mutant adenovirus," *The Journal of Clinical Investigation*, 108(7):981-990, October 2001.
	FM		Miller, J.R. et al., "Mechanism and function of signal transduction by the Wnt/β-catenin and Wnt/Ca^{2+} pathways," *Oncogene 18*: 7860-7872, 1999.
	FN		Miloloza, A. et al., "The TSC1 gene product, hamartin, negatively regulates cell proliferation," *Human Molecular Genetics*, 9(12):1721-1727, 2000.
	FO		Misner, D.L. et al., "Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity," *PNAS*, 98(20):11714-11719, September 25, 2001.
	FP		Molenaar, M. et al., "XTcf-3 Transcription Factors Mediates β-Catenin-Induced Axis Formation in Xenopus Embryos," *Cell*, 86:391-399, August 9, 1996.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	GA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	GB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	GC		Moon, R.T. et al., "WNTs modulate cell fate and behavior during vertebrate development," *Trends in Genetics*, 13(4):157-162, April 1997.
	GD		Morin, P.J. et al., "Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC," *Science 275*: 1787-1790, March 21, 1997.
	GE		Morin, P.J. et al., "Apoptosis and *APC* in colorectal tumorigenesis," *Proc. Natl. Acad. Sci. USA*, 93:7950-7954, July 1996.
	GF		Murai, K.K. et al, "Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling," *Nature Neuroscience*, 6(2):153-160, February 2003.
	GG		Nishimura, M. et al., "Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of β-catenin, a component of the presenilin protein complex," *Nature Medicine*, 5(2):164-169, February 1999.
	GH		Nusse and Varmus, "*Wnt* Genes," *Cell*, 69:1073-1087, June 26, 1992.
	GI		Obrecht, D. et al., "Novel peptide mimetic building blocks and strategies for efficient lead finding," *Advances in Medicinal Chemistry*, 4:1-68, 1999.
	GJ		Orford, K. et al., "Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-independent Growth, Anoikis, and Radiation-induced Cell Cycle Arrest," *The Journal of Cell Biology*, 146(4):855-867, August 23, 1999.
	GK		Patapoutian and Reichardt, "Roles of Wnt proteins in neural development and maintenance," *Curr. Opin. Neurobiol.*, 10(3):392-399, 2000.
	GL		Peifer and Polakis, "Wnt Signaling in Oncogenesis and Embryogenesis – a Look Outside the Nucleus," *Science*, 287:1606-1609, March 3, 2000.
	GM		Polakis P., "Wnt signaling and cancer," *Genes & Development*, 14:1837-1851, 2000.
	GN		Randolph, J.T. et al., "Major Simplifications in Oligosaccharide Syntheses Arising from a Solid-Phase Based Method: An Application to the Synthesis of the Lewis b Antigen," *Journal of the American Chemical Society 117*: 5712-5719, 1995.
	GO		Rebel, V.I. et al., "Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal," *PNAS*, 99(23):14789-14798, November 12, 2002.
	GP		Reed, J.C., "The Survivin saga goes in vivo," *The Journal of Clinical Investigation*, 108(7):965-969, October 2001.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	HA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	HB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	HC		Reya, T. et al., "A role of Wnt signaling in self-renewal of haematopoietic stem cells," *Nature*, 423:409-414, May 22, 2003.
	HD		Rodova, M. et al., "The Polycystic Kidney Disease-1 Promoter Is a Target of the β-Catenin/T-cell Factor Pathway," *The Journal of Biological Chemistry*, 277(33):29577-29583, 2002.
	HE		Roose, J. et al., "Synergy Between Tumor Suppressor *APC* and the β-Catenin-Tcf4 Target *Tcf1*," *Science*, 285:1923-1926, September 17, 1999.
	HF		Rubinfeld, B. et al., "Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly," *Science*, 272:1023-1026, May 17, 1996.
	HG		Rubinfeld, B. et al., "Stabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines," *Science*, 275:1790-1792, March 21, 1997.
	HH		Sakanaka and Williams, "Functional Domains of Axin. Importance of the C Terminus as an Oligomerization Domain," *The Journal of Biological Chemistry*, 274(20):14090-14093, May 14, 1999.
	HI		Sakanaka, C. et al., "Bridging of β-catenin and glycogen synthase kinase-3β by Axin and inhibition of β-catenin-mediated transcription," *Proc. Natl. Acad. Sci. USA*, 95:3020-3023, March 1998.
	HJ		Sen, M. et al., "Expression of function of wingless and frizzled homologs in rheumatoid arthritis," *PNAS*, 97(6):2791-2796, March 14, 2000.
	HK		Shintani, S. et al., "Infrequent Alternations of RB Pathway (Rb-p16^{INK4A}-cyclinD1) in Adenoid Cystic Carcinoma of Salivary Glands," *Anticancer Research*, 20:2169-2176, 2000.
	HL		Shikama et al., "The p300/CBP family: integrating signals with transcription factors and chromatin," *Trends in Cell Biology*, 7:230-236, June 1997.
	HM		Shtutman, M. et al., "The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway," *Proc. Natl. Acad. Sci.USA*, 96:5522-5527, May 1999.
	HN		Soriano, S. et al., "Presenilin 1 Negatively Regulates β-Catenin/T Cell Factor/Lymphoid Enhancer Factor-1 Signaling Independently of β-Amyloid Precursor Protein and Notch Processing," *The Journal of Cell Biology*, 152(4):785-794, February 19, 2001.
	HO		Stein, R.W. et al., "Analysis of E1A-Mediated Growth Regulation Functions: Binding of the 300-Kilodalton Cellular Product Correlates with E1A Enhancer Repression Function and DNA Synthesis-Inducing Activity," *Journal of Virology*, 64(9):4421-4427, September 1990.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	IA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	IB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	IC		Stewart and Young, "Solid Phase Peptide Synthesis," *Pierce Chemical Company*, Second Edition, Rockford, Illinois, 1984, Table of Contents (6 pages).
	ID		Strovel and Sussman, "Transient Overexpression of Murine *Dishevelled* Genes Results in Apoptotic Cell Death," *Experimental Cell Research*, 253:637-648, 1999.
	IE		Su, L-K. et al., "Association of the APC Tumor Suppressor Protein with Catenins," *Science*, 262:1734-1737, December 10, 1993.
	IF		Takemaru and Moon, "The Transcriptional Coactivator CBP Interacts with β-Catenin to Activate Gene Expression," *The Journal of Cell Biology*, 149(2):249-254, April 17, 2000.
	IG		Tetsu and McCormick, "β-Catenin regulates expression of cyclin D1 in colon carcinoma cells," *Nature*, 398:422-426, April 1, 1999.
	IH		Tong, D. et al., "5-Fluorouracil-induced apoptosis in cultured oral cancer cells," *Oral Oncology*, 36:236-241, 2000.
	II		Tumelty, D. et al., "Immobilised, Activated Peptides as Reagents for Cyclic and Derivatised Peptide Libraries," *J. Chem. Soc. Chem. Commun.*, 1067-1068, 1994.
	IJ		Uthoff, S.M.S. et al., "Identification of candidate genes in ulcerative colitis and Crohn's disease using cDNA array technology," *International Journal of Oncology*, 19:803-810, 2001.
	IK		Wilkinson, D.G., "Multiple Roles of EPH Receptior and Ephrins in Neural Development,"*Nature Reviews, Neuroscience*, 2:155-164, March 2001.
	IL		Xia, X. et al., "Loss of presenilin 1 is associated with enhanced β-catenin signaling and skin tumorigenesis," *PNAS*, 98(19):10863-10868, September 11, 2001.
	IM		Yost, C. et al., "The axis-inducing activity, stability, and subcellular distribution of β-catenin is regulated in *Xenopus* embryos by glycogen synthase kinase 3," *Genes & Development*, 10:1443-1454, 1996.
	IN		Yu, G. et al., "The Presenilin 1 Protein Is a Component of a High Molecular Weight Intracellular Complex That Contains β-Catenin," *The Journal of Biological Chemistry*, 273(26):16470-16475, June 26, 1998.
	IO		Zaloom and Roberts, "Preparation of Azido Derivatives from Amino Acids and Peptides by Diazo Transfer," *J. Org. Chem.*, 46:5173-5176, 1981.

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 200146.402C4	APPLICATION NO. 10/826,972
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		APPLICANTS Sung Hwan Moon et al.	
		FILING DATE April 16, 2004	GROUP ART UNIT 1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	JA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	JB					

OTHER ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	JC		Zhang, T. et al., "Evidence That APC Regulates Survivin Expression: A Possible Mechanism Contributing to the Stem Cell Origin of Colon Cancer," *Cancer Research*, 62:8664-8667, December 15, 2001.
	JD		Zhang, Z. et al., "Destabilization of β-catenin by mutations in presenilin-1 potentiates neuronal apoptosis," *Nature*, 395:698-702, October 15, 1998.
	JE		
	JF		
	JG		
	JH		
	JI		
	JJ		
	JK		
	JL		
	JM		
	JN		
	JO		
	JP		
	JQ		

EXAMINER	DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).